Hospital
Temecula Valley Hospital INC
Temecula Valley Hospital INC was paid $14.45M by Medicaid between Jan 2018 and Dec 2024, across 174 billing codes. Its largest line is 0450, Emergency room services — 13% of everything it billed.
33Billing provider infoTEMECULA VALLEY HOSPITAL INC
TEMECULA, CA 92592
TEMECULA, CA 92592
33aNPI1679816201assigned 04/02/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.45M
24GClaims433,386
24DCodes billed174
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#155 of 410
Median peer was paid$6.90M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,652 | $1.73M | |
| 2019 | 45,517 | $1.28M | |
| 2020 | 57,302 | $1.67M | |
| 2021 | 63,305 | $2.23M | |
| 2022 | 69,159 | $2.55M | |
| 2023 | 67,547 | $2.26M | |
| 2024incomplete | 65,904 | $2.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 13% | 33,541 | 30,236 | $1.81M |
| L8699 | Prosthetic implant, not otherwise specified | 8.3% | 412 | 342 | $1.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.2% | 20,526 | 18,645 | $1.19M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.9% | 3,759 | 3,656 | $1.14M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.5% | 11,448 | 10,600 | $944K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 5,146 | 5,005 | $603K |
| 93975 | 3.4% | 1,535 | 1,481 | $487K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.3% | 16,142 | 14,784 | $476K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.8% | 2,717 | 2,651 | $409K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.8% | 7,621 | 6,975 | $403K |
| 99499 | 2.7% | 4,232 | 3,857 | $394K | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 3,035 | 2,821 | $350K |
162 more codes
| 80053 | Comprehensive metabolic panel | 1.9% | 24,500 | $280K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.9% | 1,591 | $271K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 2,586 | $247K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 29,297 | $240K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 972 | $239K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 6,395 | $237K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 3,151 | $233K |
| 99284 | Emergency room visit (serious) | 1.6% | 2,308 | $225K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 13,256 | $205K |
| 84484 | 1.1% | 14,418 | $153K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,940 | $141K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,228 | $141K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,080 | $121K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,348 | $119K |
| 93971 | <1% | 830 | $108K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,528 | $101K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,051 | $99K |
| 83880 | <1% | 2,689 | $83K | |
| 83690 | <1% | 10,954 | $82K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 884 | $77K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 774 | $71K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 344 | $57K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,089 | $56K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,222 | $55K |
| J3490 | Unclassified drugs | <1% | 17,337 | $47K |
| 0710 | <1% | 752 | $44K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 853 | $41K |
| 99070 | <1% | 18,089 | $40K | |
| 83605 | <1% | 2,934 | $38K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,467 | $38K |
| 81001 | <1% | 10,523 | $37K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,143 | $37K |
| Z7502 | <1% | 926 | $36K | |
| 73630 | <1% | 1,203 | $35K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 373 | $34K |
| 73610 | <1% | 1,106 | $34K | |
| 84703 | <1% | 3,754 | $30K | |
| 81025 | <1% | 5,890 | $30K | |
| 73562 | <1% | 1,078 | $29K | |
| 85730 | <1% | 4,584 | $28K | |
| 73030 | <1% | 918 | $27K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,714 | $27K |
| 0762 | <1% | 68 | $27K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,440 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,218 | $25K |
| 73130 | <1% | 872 | $25K | |
| 84702 | <1% | 1,439 | $24K | |
| 83735 | <1% | 3,503 | $23K | |
| 85610 | <1% | 5,493 | $21K | |
| 87040 | <1% | 1,775 | $21K | |
| 85379 | <1% | 1,696 | $19K | |
| 87634 | <1% | 250 | $18K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 380 | $18K |
| 76801 | <1% | 193 | $18K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 521 | $18K |
| 72100 | <1% | 534 | $17K | |
| 73110 | <1% | 564 | $17K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,043 | $17K |
| 90715 | <1% | 487 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 101 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,214 | $15K |
| 84439 | <1% | 1,588 | $15K | |
| 87276 | <1% | 1,575 | $15K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,836 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,476 | $13K |
| 81003 | <1% | 5,060 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 455 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 455 | $12K |
| 87430 | <1% | 1,064 | $12K | |
| 99221 | <1% | 59 | $11K | |
| 87275 | <1% | 1,580 | $11K | |
| 87186 | <1% | 1,278 | $11K | |
| 87077 | <1% | 1,334 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 263 | $11K |
| 0250 | <1% | 3,176 | $10K | |
| 0270 | <1% | 3,533 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,821 | $10K |
| 70496 | <1% | 36 | $10K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,053 | $9K |
| 99152 | <1% | 242 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,634 | $8K |
| 85027 | <1% | 1,242 | $8K | |
| 87561 | <1% | 194 | $7K | |
| 82962 | <1% | 2,138 | $7K | |
| 70486 | <1% | 54 | $7K | |
| 87081 | <1% | 915 | $6K | |
| G0378 | Hospital observation service, per hour | <1% | 75 | $6K |
| 70498 | <1% | 27 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,073 | $5K |
| 73080 | <1% | 175 | $5K | |
| 36000 | <1% | 792 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,884 | $5K |
| 93970 | <1% | 27 | $5K | |
| 93458 | <1% | 12 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 182 | $4K |
| 86901 | <1% | 1,211 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,681 | $4K |
| 86900 | <1% | 1,211 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 78 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,207 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 42 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,061 | $3K |
| 82550 | <1% | 388 | $3K | |
| 74018 | <1% | 132 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,247 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 69 | $3K |
| 99199 | Unlisted special service, procedure or report | <1% | 56 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 45 | $3K |
| 99217 | <1% | 74 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 480 | $2K |
| 86850 | <1% | 460 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,460 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 96 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,688 | $2K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 103 | $2K |
| 71010 | <1% | 76 | $2K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 57 | $2K |
| 72040 | <1% | 51 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 12 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 468 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 191 | $1K |
| 73090 | <1% | 54 | $1K | |
| 73590 | <1% | 52 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 245 | $1K |
| 71020 | <1% | 30 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 32 | $1K |
| 96376 | <1% | 136 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 69 | $1K |
| 99153 | Mod sedat endo service >5yrs | <1% | 82 | $1K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 34 | $1K |
| 82553 | <1% | 91 | $1K | |
| 73502 | <1% | 24 | $961.23 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 12 | $912.12 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $821.11 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 56 | $820.92 |
| 82803 | <1% | 40 | $749.74 | |
| 12001 | <1% | 12 | $640.85 | |
| 87420 | <1% | 66 | $584.12 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 101 | $560.38 |
| A9270 | Non-covered item or service | <1% | 613 | $489.43 |
| 10060 | <1% | 14 | $343.26 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 13 | $289.16 |
| 73140 | <1% | 13 | $280.92 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 26 | $270.90 |
| 84100 | <1% | 51 | $255.57 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 278 | $241.30 |
| 86141 | <1% | 24 | $229.73 | |
| 86140 | <1% | 37 | $226.78 | |
| 94664 | <1% | 16 | $217.44 | |
| 88342 | <1% | 17 | $183.05 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 12 | $160.16 |
| 87070 | <1% | 14 | $114.82 | |
| 80061 | Lipid panel | <1% | 16 | $106.96 |
| 83721 | <1% | 16 | $94.18 | |
| 86308 | <1% | 14 | $79.46 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 25 | $69.66 |
| 0272 | <1% | 12 | $65.10 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 29 | $49.60 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 16 | $46.50 |
| 85652 | <1% | 12 | $34.35 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 15 | $23.36 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $10.35 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.